Multiple studies have indicated that CDK4/6 inhibitors are linked with an elevated risk of various hematologic adverse events, such as neutropenia, anemia, and thrombocytopenia [10–12]. The gene discussed is CDK4; the disease is Decreased total neutrophil count.